| Previous Close | 0.115 |
| Open | 0.000 |
| Bid | 0.000 x 0 |
| Ask | 0.000 x 0 |
| Day's Range | 0.000 - 0.000 |
| 52 Week Range | |
| Volume | 0 |
| Avg. Volume | 793,740 |
| Market Cap | 25.067M |
| Beta | 5.50 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.036 |
| Earnings Date | Nov 12, 2018 - Nov 16, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.34 |
Innovus Pharmaceuticals, Inc. , an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced that Dr.
NEW YORK, NY / ACCESSWIRE / August 21, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update on Innovus Pharmaceuticals, Inc. (INNV) and has raised its target price to $0.75. Innovus Pharmaceuticals, Inc. (OTCQB: INNV, "Innovus") is a fast-growing commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter (OTC) medicine and consumer care products to improve men and women's health, respiratory disease and vitality. Led by CEO Dr. Bassam Damaj, Innovus is based in San Diego, CA and has demonstrated robust growth in its product offerings and annual revenues since we initiated coverage on the company in September 2014.
Beyond Human™ Sales & Marketing Strategy Results in 258.7% Net Revenue Growth Compared to Same Period in 2017
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it has entered into a purchase agreement with the nationwide retail store chain Showcase, a Canadian company for its drug Apeaz®, for arthritis pain relief. Apeaz® will be available in Showcase’s 110 stores across the United States and Canada and on its www.ShopAtShowcase.com portal starting mid-August, 2018.
Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced the filing by it for regulatory approval in Canada for its (1) Xyralid® Suppositories drug for the relief of hemorrhoidal swelling, (2) Beyond Human® Testosterone to promote and maintain testosterone levels in men and (3) RecalMax™ for cognitive health and mental sharpness. The regulatory approval process for the three products may take anywhere up to 210 days for approval depending on the application.
Innovus Pharmaceuticals, Inc. today announced that the Company will release its June 30, 2018 second quarter financial results on Tuesday, August 14, 2018, after the close of the U.S.
Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced that it has entered into a pilot program with the nationwide pharmaceutical chain CVS Pharmacy, Inc. (“CVS”), which is a subsidiary of CVS Health Corp (CVS), to sell the Company’s product Androferti®, to increase sperm quality. If successful, the CVS pilot program could lead to the national pharmacy stocking and selling Androferti® on a scalable level nationwide and could expand to add additional Innovus Pharma products.
Preliminary Quarterly Revenue Increase of 47-51% and Comparable 2017 Second Quarter Increase of 330-340% and Fiscal Year 2018 Net Revenue Annual Guidance Adjusted Upwards to at Lea
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced the approval from Amazon® for the expansion of its Amazon® stores to five European countries namely the United Kingdom, France, Germany, Spain and Italy. The additional store will increase the Company’s European presence and help Innovus Pharma’s customers access its products in English, French, German, Spanish and Italian.
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced the launch of its product AllerVarx™, which is a clinically proven, Natural Health Product approved by Health Canada to help reduce symptoms of allergic rhinitis such as nasal discharge, sneezing, nasal congestion and itching. Innovus Pharma launched AllerVarx™ in Canada through the Company’s website and its Canadian Beyond Human™ marketing and sales platform.
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced the approval by Health Canada of its product ProstaGorx™ as a Natural Health Product (NPN #80085717) for the relief of urologic symptoms (e.g. Innovus Pharma expects to launch ProstaGorx™ in the next few months through the Company’s website and its Canadian Beyond Human™ marketing and sales platform.
Innovus Pharmaceuticals, Inc. , an emerging over-the-counter consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, today announced that Dr.
NEW YORK, NY / ACCESSWIRE / May 30, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update on Innovus Pharmaceuticals, Inc. (INNV) with a Target Price of $0.70. Innovus Pharmaceuticals, Inc. (OTCQB: INNV, ''Innovus'') is a fast-growing commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter (OTC) medicine and consumer care products to improve men and women's health, respiratory disease and vitality. Led by CEO Dr. Bassam Damaj, Innovus is based in San Diego, CA and has demonstrated robust growth in its product offerings and annual revenues since we initiated coverage on the company in September 2014, with revenues growing from approximately $1.0mn in 2014 to $8.8mn in 2017 and guidance for more than $18mn in revenues in 2018.
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that Robert Verfurth, the Company’s Vice President, Sales and Marketing, will exhibit through a booth the Company’s primary allergy products, FlutiCare® and AllerVarx™ from Sunday, May 20, 2018 to Tuesday, May 22, 2018 at the San Diego Convention Center, 111 West Harbor Drive, San Diego, CA 92101. Interested persons can learn more about the event at http://conference.thoracic.org.
Innovus Pharmaceuticals, Inc. , an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced the launch of its product Vesele®, approved by Health Canada for the increase in vasodilation through nitric oxide production, in Canada.
Innovus Pharmaceuticals, Inc., , today announced first quarter 2018 net revenue of $4.5 million compared to $2.2 million in net revenue for the same period in 2017.
Innovus Pharmaceuticals, Inc. (“Innovus Pharma”) (INNV), today announced that the Company will release its March 31, 2018 first quarter financial results on Monday, May 14, 2018, after the close of the U.S. financial markets. The Company will host a conference call at 4:15 p.m. ET/1:15 p.m. PT on the same day to discuss the financial results and recent business developments. To participate in the call, please dial 1-877-883-0383 for domestic callers or 1-412-902-6506 for international callers or 1-877-885-0477 for Canadian callers and Participant Elite Entry Number: 9576665.
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced the launch of its lidocaine-based cream Xyralid®, for the relief of pain and symptoms caused by hemorrhoids. Xyralid® received a Product License Application (“PLA”) in Canada and the product is available as an over-the-counter (“OTC”) or behind the counter drug and will not require a prescription.
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, announced today the hiring of Ryan Selhorn, CPA as its new Vice President, Chief Financial Officer effective as of April 27, 2018. Mr. Selhorn is an industry veteran whose financial and public accounting skills as well as his experience as the Chief Financial Officer consultant for Dare Biosciences, Inc. (DARE).
Innovus Pharmaceuticals, Inc. , an emerging over-the-counter consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, announced today the launch of its product Apeaz™, a cream for the relief of arthritis ...
Innovus Pharmaceuticals, Inc. , an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that the U.S.
NEW YORK, NY / ACCESSWIRE / April 10, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued ...
Innovus Pharmaceuticals, Inc., , today announced full year 2017 net revenue of $8.8 million compared to $4.8 million in revenue for the same period in 2016 and fourth quarter of 2017 net revenue of $2.4 million compared to $1.7 million in revenue for the same period in 2016.